Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Recruiting 2Completed 2

Sponsor Class

INDUSTRY 8OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4Breast 1

Conditions

Ovarian Neoplasms 4Triple Negative Breast Neoplasms 3Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Breast Neoplasms 2

Interventions

Carboplatin 156Paclitaxel 154Bevacizumab 96Cyclophosphamide 61Gemcitabine 46olaparib 45Cisplatin 45Topotecan 44niraparib 40liposomal doxorubicin 40pembrolizumab 38Surveys and Questionnaires 33Filgrastim 31Hyperthermic Intraperitoneal Chemotherapy 29Docetaxel 27Taxes 25Blood Specimen Collection 24fludarabine 23Drug Therapy 23Cytoreduction Surgical Procedures 23Peripheral Blood Stem Cell Transplantation 21Etoposide 21Doxorubicin 21Magnetic Resonance Spectroscopy 20durvalumab 17Specimen Handling 17Albumin-Bound Paclitaxel 17Immunoglobulin G 15Disulfides 15Letrozole 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Ovarian Neoplasms × mirvetuximab soravtansine × Clear all
NCT05887609 2026-06-04

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

University of Colorado, Denver

Phase 2 Recruiting
53 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04606914 2025-09-08

Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

University of Alabama at Birmingham

Phase 2 Recruiting
70 enrolled
Gynecologic

Ovarian Neoplasms

NCT03552471 2025-02-13

Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
25 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02996825 2024-04-02

Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer

City of Hope Medical Center

Phase 1 Completed
44 enrolled
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡